NovoCure (NASDAQ: NVCR)
Key Data Points
NovoCure Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
NovoCure Company Info
Novocure's tumor-treating field devices use electric fields to disrupt the replication of cancer cells.
News & Analysis
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Why Novocure Stock Was Winning Big This Week
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
NovoCure Beats Q3 Revenue, EPS Estimates
The cancer-treatment specialist demonstrated strong revenue growth, but on the bottom line, it's still losing money.
Why NovoCure Stock Dived by 13% This Week
Investors found the announced changes to the company's C-suite unsettling.
NovoCure's Q2 Revenue Soars by 10.7%
The oncology treatment pioneer delivered a robust report showcasing significant revenue growth and a clinical trial success.
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

Why NovoCure's Regulatory News Is a Huge Win for Investors
The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.

3 Medical Device Companies for Your Watchlist
Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.